We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE to Consider Burden of Illness, Societal Impact in Drug Assessments
NICE to Consider Burden of Illness, Societal Impact in Drug Assessments
The UK’s health cost-benefit watchdog is developing new “burden of illness” and “societal impact” measurements to use when assessing new drugs for government reimbursement.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor